Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

Suven Pharmaceuticals Ltd - 543064 - Board to consider Q3 results & Interim Dividend on Feb 10, 2021

 Suven Pharmaceuticals Ltd has informed BSE that a Meeting of the Board of Directors of the Company will be held on February 10, 2021, inter alia, to consider and approve the following matter(s):1. The Un-audited Financial Results (Standalone and Consolidated) of the Company under Ind AS for the quarter and nine months ended December 31, 2020 (Q3).2. To consider declaration of Interim Dividend, if any, for the financial year 2020-21 and related matters etc.Further note that TRADING WINDOW for dealing in the securities of the Company is already closed from January 01, 2021 as per PIT Code of the Company. Trading window will be opened from February 13, 2021.
03-02-2021
Bigul

Suven Pharmaceuticals Ltd - 543064 - Board Meeting Intimation for Intimation Of Board Meeting Of The Company To Be Held On Wednesday, The 10Th February, 2021

 Suven Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/02/2021 ,inter alia, to consider and approve With reference to above subject, pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please note that a Meeting of the Board of Directors of the Company will be held on Wednesday, the 10th February, 2021 at 11:30 a.m. at the Registered Office, SDE Serene Chambers, 3rd Floor, Road No 5, Banjara Hills, Hyderabad - 500034 of the Company, to consider, inter alia, and approve the following matter(s): 1) The Un-audited Financial Results (Standalone and Consolidated) of the Company under Ind AS for the quarter and nine months ended December 31, 2020. 2) To consider declaration of Interim Dividend, if any, for the financial year 2020-21 and related matters etc. and 3) Advance intimation under regulation 42: The Record Date for the purpose of payment of interim dividend to eligible shareholders would be 18th February, 2021, if considered and approved by the Board.
03-02-2021
Bigul

Suven Pharmaceuticals Ltd - 543064 - Statement Of Investor Complaints For The Quarter Ended December 2020

 No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 047470 Name of the Signatory :- K Hanumantha RaoDesignation :- Company Secretary and Compliance Officer
20-01-2021
Bigul

Suven Pharmaceuticals Ltd - 543064 - Shareholding for the Period Ended December 31, 2020

 Suven Pharmaceuticals Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2020. For more details, kindly Click here
18-01-2021
Bigul

Select pharma shares rally; Suven Pharma up 13%, Laurus nears record high

 Healthcare companies to post decent growth in revenues in Q3FY21
14-01-2021
Bigul

Suven Pharmaceuticals Ltd - 543064 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

 Pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations 2018, please find enclosed herewith the Confirmation Certificate issued by KFin Technologies Private Limited, Registrar and Share Transfer Agents of the Company, for the quarter ended December 31, 2020
11-01-2021
Bigul

Suven Pharmaceuticals Ltd - 543064 - Closure of Trading Window

 We wish to inform you that the "Trading Window" for dealing in the securities of the Company will be closed for the Designated Persons, their immediate relatives covered under the said Code of the Company from 1st January, 2021 and the same will remain closed till 48 hours after the declaration of Financial Results for the third quarter/ nine months ending 31st December, 2020, to the public, in terms of the Code of Conduct of the Company under the SEBI (Prohibition of Insider Trading) Regulations, 2015.
31-12-2020
Bigul

Suven Pharmaceuticals Ltd - 543064 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 Pursuant to Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the Company has received intimation from our RTA dtd. 04-12-2020 regarding issued duplicate share certificate(s) in lieu of the loss of original share certificate(s) to the following shareholders(s).
05-12-2020
Bigul

Suven Pharmaceuticals Ltd - 543064 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 We wish to inform you that management of Suven Pharma is giving corporate presentation in 'Prabhudas Leeladhar Investor Conference - PL - Pharma Day' with fund managers and analysts online meeting organized by Prabhudas Leeladhar on 4th December, 2020 at 11:30 a.m. IST.
03-12-2020
Bigul

Suven Pharmaceuticals Ltd - 543064 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 We wish to inform you that management of Suven Pharma is giving corporate presentation in 'Kotak Securities Annual Investor Conference - Connecting Growth 2020' with fund managers and analysts online meeting organized by Kotak Securities on 26th November, 2020 at 11:00 a.m. IST.
25-11-2020
Next Page
Close

Let's Open Free Demat Account